700,000 Seniors Now on GLP-1 Drugs After Medicare Coverage Expands

Eli Lilly's chief executive revealed Tuesday that 700,000 new Medicare beneficiaries have begun GLP-1 weight-loss and diabetes treatments since the federal program expanded coverage in July, marking a significant surge in access for older Americans who were previously shut out of the blockbuster drug class.

The most striking detail: roughly 70% of those newly covered seniors chose Lilly medications over rival offerings, a figure that underscores the Indianapolis-based pharmaceutical giant's commanding position in a market that has reshaped the broader healthcare landscape. The disclosure gives Wall Street and health policy observers the clearest picture yet of how quickly Medicare expansion is translating into real-world patient volume.

Read more Texas Senate Race Tightens as Talarico Holds Narrow Lead →

The rollout represents a meaningful milestone for GLP-1 access policy. For years, Medicare was barred from covering obesity drugs, leaving millions of seniors without affordable options even as private insurers and employers gradually broadened their own formularies. The July coverage change reversed that long-standing restriction and appears to be driving adoption at a pace that caught even some industry analysts off guard.

While the 700,000 figure reflects early momentum, analysts will be watching whether uptake sustains or accelerates as awareness grows among the roughly 67 million Americans enrolled in Medicare. Lilly's 70% share among new starters also raises competitive pressure on Novo Nordisk, whose semaglutide franchise has dominated GLP-1 headlines globally, to respond with pricing or access strategies aimed at the senior market.

Continue reading at US Top News and Analysis.